Merck News (NYSE:MRK)

DateTimeSource
Headline
02/16/20178:00AMBWMerck’s Fight Against Infectious Disease Goes Digital with Launch of ILÚM Health Solutions
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the launch of ILÚM Health Solutions, which provides enterprise-wide disease management tools and services to enable improved outcomes for patients with infectious diseases, such as sepsis and pneumonia, while supporting antimicrobial... More...>>
02/14/20177:06PMDJNMerck Stops Clinical Trial of Alzheimer's Drug
By Peter Loftus Merck & Co. said Tuesday it stopped a clinical trial of an experimental Alzheimer's drug because it wasn't helping patients, the latest setback in the pharmaceutical industry's quest to find a better treatment for the brain disorder. An outside committee monitoring the study of more than... More...>>
02/14/20175:00PMBWMerck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer’s Disease to Stop f...
APECS Study in People with Prodromal Alzheimer’s Disease to Continue Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it will be stopping protocol 017, also known as the EPOCH study, a Phase 2/3 study evaluating verubecestat, an investigational small molecule inhibitor of the... More...>>
02/14/20174:05PMBWMerck’s Doravirine, an Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV-1 In...
Data Presented at CROI Showed Doravirine Was Non-inferior to Ritonavir-boosted Darunavir in Treatment-naïve Adults after 48 weeks of Treatment Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results of a pivotal Phase 3 clinical trial evaluating the safety and efficacy of doravirine... More...>>
02/11/20173:02AMDJNReckitt Agrees to Mead Deal -- WSJ
By Saabira Chaudhuri LONDON -- Reckitt Benckiser Group PLC on Friday said it agreed to buy baby-food maker Mead Johnson Nutrition Co. for $16.6 billion, a deal that will almost double the size of the British company's consumer-health business and push it deeper into emerging markets. Reckitt, whose lineup includes... More...>>
02/10/20178:22AMDJNReckitt Benckiser to Buy Mead Johnson for $16.6 Billion -- 4th Update
By Saabira Chaudhuri LONDON-- Reckitt Benckiser Group PLC on Friday said it agreed to buy baby-food maker Mead Johnson Nutrition Co. for $16.6 billion, a deal that will almost double the size of the British company's consumer-health business and help it push deeper into emerging markets. The U.K. company, which owns... More...>>
02/10/20176:25AMDJNReckitt Benckiser to Buy Mead Johnson for $16.6 Billion -- 3rd Update
By Saabira Chaudhuri LONDON-- Reckitt Benckiser Group PLC on Friday said it agreed to buy baby-food maker Mead Johnson Nutrition Co. for $16.6 billion, a deal that will almost double the size of the British company's consumer-health business and help it push deeper into emerging markets. The U.K. company, which owns... More...>>
02/10/20174:21AMDJNReckitt Benckiser to Buy Mead Johnson for $16.6 Billion -- 2nd Update
By Saabira Chaudhuri LONDON-- Reckitt Benckiser Group PLC on Friday said it agreed to buy baby-food maker Mead Johnson Nutrition Co. for $16.6 billion, a deal that will almost double the size of the British company's consumer-health business and help it push deeper into emerging markets. The U.K. company, which owns... More...>>
02/09/20179:00AMBWMerck Foundation Announces Six Program Grant Recipients for Alliance to Advance Patient-Centered Cancer Care
Alliance Aims to Reduce Disparities in Access to High-Quality Cancer Care The Merck Foundation (Foundation), announced today the selection of the six program sites and National Program Office forming the Alliance to Advance Patient-Centered Cancer Care (the Alliance). With $15 million in funding from the Foundation over... More...>>
02/07/20177:01PMDJNGilead Posts Profit, Revenue Declines -- Update
By Anne Steele and Jonathan D. Rockoff Gilead Sciences Inc.'s sales of hepatitis C drugs Harvoni and Sovaldi plunged in the latest quarter compared with a year ago, while the company's warning that the drugs' sales would keep falling prompted a 2017 forecast that disappointed analysts. Shares in the biopharmaceutical... More...>>
02/07/20175:31PMDJNGilead Posts Profit, Revenue Declines
By Anne Steele Gilead Sciences Inc.'s sales of hepatitis C drugs Harvoni and Sovaldi continued to decline in the latest quarter, though sales of its cheaper Epclusa buoyed the top line above estimates. Shares in the biopharmaceutical company, which faces challenges from rival drugs and pricing pressures, dropped 4.3... More...>>
02/03/20176:45AMBWFDA Accepts Two sBLAs for Merck’s KEYTRUDA® (pembrolizumab) for Locally Advanced or Metastatic Urothelial Cancer in Cispla...
KEYTRUDA Also Receives Breakthrough Therapy Designation for Second-Line Treatment Based on KEYNOTE-045, Which Includes Primary Endpoints of Overall Survival and Progression-Free Survival Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA... More...>>
02/02/201711:54AMDJNMerck Revenue Declines As Generic Competition Hurts Results -- Update
By Austen Hufford and Peter Loftus Drugmaker Merck & Co. posted a revenue decline in its latest quarter as generic competition for some of its top-selling products hurt results, though its sales still exceeded expectations. Merck's shares rose 2.7% Thursday morning, as the company also issued a financial forecast... More...>>
02/02/201711:52AMDJNCorrection to Merck Earnings Story
Merck lost U.S. market exclusivity for its cholesterol drug Zetia. "Merck Revenue Declines As Generic Competition Hurts Results," at 7:47 a.m. ET, misspelled Zetia in the 3rd paragraph. (Feb. 2) (END) Dow Jones Newswires February 02, 2017 11:37 ET (16:37 GMT) Copyright (c) 2017 Dow Jones & Company, Inc. More...>>
02/02/20178:17AMDJNMerck Revenue Declines As Generic Competition Hurts Results
By Austen Hufford Merck & Co. posted a revenue decline in its latest quarter as generic competition hurt results, though the top line was still better than expectations. Shares rose 1.5% in premarket trading. Pharmaceutical revenue for the fourth quarter decreased 1.4% to $8.9 billion, driven by the loss of U.S. market... More...>>
02/02/20176:45AMBWMerck Announces Fourth-Quarter and Full-Year 2016 Financial Results
Fourth-Quarter 2016 Worldwide Sales Were $10.1 Billion, a Decrease of 1 Percent, Including a 1 Percent Negative Impact from Foreign Exchange; Full-Year 2016 Worldwide Sales Were $39.8 Billion, an Increase of 1 Percent, Including a 2 Percent Negative Impact from Foreign Exchange Fourth-Quarter 2016 GAAP EPS Was $0.42; Fourth-Quarter... More...>>
02/01/20173:02AMDJNMore Headaches for Drugmakers -- WSJ
By Peter Loftus and Preetika Rana The U.S. pharmaceutical industry has been under pressure over high and rising drug prices. Now after criticism from the White House, it's feeling the heat for where it makes its products, too. "I want you to manufacture in the United States," President Donald Trump told... More...>>
01/31/20176:54PMDJNTrump's Criticism of Imports Adds to Drugmakers' Headaches -- Update
By Peter Loftus and Preetika Rana The U.S. pharmaceutical industry has been under pressure over high and rising drug prices. Now after criticism from President Trump, it's feeling the heat for where it makes its products, too "I want you to manufacture in the United States," President Donald Trump told several... More...>>
01/31/20174:00PMBWEuropean Commission Approves KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients with Metastatic Non-Small Cell L...
Approval Based on Data Showing Improved Overall Survival and Progression-Free Survival with KEYTRUDA Compared to Chemotherapy First Anti-PD-1 Therapy Approved in Europe for Previously Untreated Patients with Metastatic NSCLC Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European... More...>>
01/31/20172:59PMDJNTrump Tells Pharmaceutical CEOs He Wants Prices Down -- Update
By Damian Paletta WASHINGTON -- President Donald Trump on Tuesday told pharmaceutical executives that he wanted them to bring drug prices "way down," but he promised he would curb regulations and lower tax rates to boost their competitiveness. At a White House meeting, Mr. Trump said Medicare and Medicaid are... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V:us D:20170224 08:03:48